Skip to main content

Drug Interactions between Iressa and mobocertinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

gefitinib mobocertinib

Applies to: Iressa (gefitinib) and mobocertinib

Mobocertinib may decrease the blood levels and effects of gefitinib. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Contact your doctor if your condition changes. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Major

mobocertinib food

Applies to: mobocertinib

You should avoid consumption of grapefruit and grapefruit juice during treatment with mobocertinib. Grapefruit juice can increase the blood levels of mobocertinib. This may increase the risk of side effects such as diarrhea, nausea, vomiting, rash, fatigue, musculoskeletal pain, mouth sores and inflammation, heart failure, and rare but potentially serious and life-threatening irregular heart rhythm disorders. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Egfr inhibitors

Therapeutic duplication

The recommended maximum number of medicines in the 'EGFR inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'EGFR inhibitors' category:

  • Iressa (gefitinib)
  • mobocertinib

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer